[HTML][HTML] Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives
Abstract Alzheimer's disease (AD), a progressive degenerative disorder first identified by
Alois Alzheimer in 1907, poses a significant public health challenge. Despite its prevalence
and impact, there is currently no definitive ante mortem diagnosis for AD pathogenesis. By
2050, the United States may face a staggering 13.8 million AD patients. This review provides
a concise summary of current AD biomarkers, available treatments, and potential future
therapeutic approaches. The review begins by outlining existing drug targets and …
Alois Alzheimer in 1907, poses a significant public health challenge. Despite its prevalence
and impact, there is currently no definitive ante mortem diagnosis for AD pathogenesis. By
2050, the United States may face a staggering 13.8 million AD patients. This review provides
a concise summary of current AD biomarkers, available treatments, and potential future
therapeutic approaches. The review begins by outlining existing drug targets and …
以上显示的是最相近的搜索结果。 查看全部搜索结果